Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Genovés, P

Grupos

Abstract

Background Cardiac fibroblast activation protein (FAP) has an emerging role in heart failure (HF). A paradoxical reduction in its levels in pathological conditions associated with acute processes has been observed. We aimed to identify FAP cardiac tissue expression and its relationship with the main cardiac fibrosis-related signaling pathways, and to compare plasma FAP levels in acute and chronic HF patients. Methods Transcriptomic changes were assessed via mRNA/ncRNA-seq in left ventricle tissue from HF patients (n = 57) and controls (n = 10). Western blotting and immunohistochemistry were used to explore FAP protein levels and localization in cardiac tissue. ELISA was performed to examine plasma FAP levels in acute HF (n = 48), chronic HF (n = 15) and control samples (n = 7). Results FAP overexpression in cardiac tissue is related to the expression of molecules directly involved in cardiac fibrosis, such as POSTN, THBS4, MFAP5, COL1A2 and COL3A1 (P < 0.001), and is directly and inversely related to pro- and antifibrotic microRNAs, respectively. The observed FAP overexpression is not reflected in plasma. Circulating FAP levels were lower in acute HF patients than in controls (P < 0.05), while chronic HF patients did not show significant changes. The clinical variables analyzed, such as functional class or etiology, do not affect plasma FAP concentrations. Conclusions We determined that in HF cardiac tissue, FAP is related to the main cardiac fibrosis signaling pathways as well as to pro- and antifibrotic microRNAs. Additionally, an acute phase of HF decreases plasma FAP levels despite the upregulation observed in cardiac tissue and regardless of other clinical conditions.

Datos de la publicación

ISSN/ISSNe:
1479-5876, 1479-5876

Journal of Translational Medicine  BMC

Tipo:
Article
Páginas:
-
PubMed:
38297310
Factor de Impacto:
1,570 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Heart failure; FAP; Cardiac fibroblasts; Fibrosis; microRNAs; Acute heart failure

Proyectos y Estudios Clínicos

Identification of small non-coding rnas and their pathophysiological implication in heart failure. cardiac-related candidate selection in liquid biopsy for its functional characterization.

Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO

PI20/00071 . INSTITUTO DE SALUD CARLOS III . 2021

Contratos Miguel Servet 2021. Estefanía Tarazón.

Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO

CP21/00041 . INSTITUTO DE SALUD CARLOS III . 2022

Contrato PFIS 2021. Isaac Giménez

Investigador Principal: ESTEFANÍA TARAZÓN MELGUIZO

FI21/00034 . INSTITUTO DE SALUD CARLOS III . 2022

Contrato PFIS 2021. Lorena Pérez

Investigador Principal: ESTHER ROSELLÓ LLETÍ

FI21/00186 . INSTITUTO DE SALUD CARLOS III . 2022

Desarrollo de un sistema no invasivo de diagnóstico de rechazo cardíaco y de pronóstico.

Investigador Principal: ESTHER ROSELLÓ LLETÍ

CNS2022-135769 . MINISTERIO DE CIENCIA E INNOVACION . 2023

Identificacion de RNAs pequenos no codificantes en suero y su papel en la fisiopatologia de la insuficiencia cardiaca avanzada. Utilidad en la monitorizacion no invasiva de los pacientes tras el trasplante cardiaco

Investigador Principal: ESTHER ROSELLÓ LLETÍ

CIACIF/2022/429 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023

Cita

Compartir